Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 10/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.39 |
| ▸ | CES1 | P23141 | 4/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29574656 | 0.70 | FDPS (0.50) | FDPSGGPS1EP300 | |
| SCHEMBL13197140 | 0.66 | FDPS (0.53) | FDPSGGPS1EP300 | |
| SCHEMBL13201767 | 0.66 | FDPS (0.53) | FDPSGGPS1EP300 | |
| SCHEMBL12557643 | 0.65 | FDPS (0.45) | FDPSGGPS1CES1CES2EP300 | |
| SCHEMBL15732245 | 0.61 | EP300 (0.46) | FDPSGGPS1EP300HIF1AEPAS1 | |
| SCHEMBL29754238 | 0.61 | FDPS (0.48) | FDPSGGPS1 | |
| SCHEMBL20733401 | 0.61 | FDPS (0.48) | FDPSGGPS1 | |
| SCHEMBL12564885 | 0.59 | KARS1 (0.43) | FDPSGGPS1 | |
| SCHEMBL12564878 | 0.59 | KARS1 (0.43) | FDPSGGPS1 | |
| SCHEMBL18290369 | 0.58 | EP300 (0.56) | FDPSGGPS1CES1CES2EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210000841-A1 | COMPOUNDS THAT MODULATE VON WILLEBRAND FACTOR LEVELS AND THEIR USE IN THE TREATMENT OF BLOOD DISORDERS | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000841-A1 | COMPOUNDS THAT MODULATE VON WILLEBRAND FACTOR LEVELS AND THEIR USE IN THE TREATMENT OF BLOOD DISORDERS | F5, F2, F3 | FDPS 124/4885GGPS1 522/4885CES1 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.